Horizon Therapeutics (HZNP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 181,755 | 54,684 | 521,482 | 401,074 | 265,235 |
| Depreciation Amortization | 193,924 | 96,331 | 454,476 | 353,926 | 252,613 |
| Income taxes - deferred | -91,952 | -87,310 | 49,814 | 8,654 | -3,032 |
| Accounts receivable | -41,140 | 51,530 | -43,457 | -13,681 | -40,513 |
| Accounts payable and accrued liabilities | -70,233 | -78,040 | 122,232 | -855 | -11,980 |
| Other Working Capital | -146,186 | -35,068 | -11,980 | -92,414 | -152,844 |
| Other Operating Activity | 221,621 | 84,196 | 165,275 | 174,747 | 155,508 |
| Operating Cash Flow | $247,789 | $86,323 | $1,257,842 | $831,451 | $464,987 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -42,594 | -24,128 | -64,026 | -39,168 | -24,352 |
| Net Acquisitions | N/A | N/A | -3,122 | -3,122 | -3,122 |
| Purchase Of Investment | -4,183 | -2,623 | -9,236 | -7,056 | -4,847 |
| Sale Of Investment | 0 | N/A | 4,633 | 4,416 | 4,416 |
| Purchase Sale Intangibles | -15,000 | -15,000 | -62,250 | -40,000 | -25,000 |
| Other Investing Activity | -15,000 | -15,000 | -62,250 | -40,000 | -25,000 |
| Investing Cash Flow | $-61,777 | $-41,751 | $-134,001 | $-84,930 | $-52,905 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -8,000 | -4,000 | -16,000 | -12,000 | -8,000 |
| Common Stock Issued | 20,961 | 3,421 | 55,367 | 37,164 | 35,906 |
| Common Stock Repurchased | N/A | N/A | -250,078 | -88,209 | N/A |
| Other Financing Activity | -92,055 | -87,549 | -137,247 | -123,947 | -120,527 |
| Financing Cash Flow | $-79,094 | $-88,128 | $-347,958 | $-186,992 | $-92,621 |
| Exchange Rate Effect | 4,908 | 2,368 | -2,451 | -8,415 | -6,317 |
| Beginning Cash Position | 2,357,588 | 2,357,588 | 1,584,156 | 1,584,156 | 1,584,156 |
| End Cash Position | 2,469,414 | 2,316,400 | 2,357,588 | 2,135,270 | 1,897,300 |
| Net Cash Flow | $111,826 | $-41,188 | $773,432 | $551,114 | $313,144 |
| Free Cash Flow | |||||
| Operating Cash Flow | 247,789 | 86,323 | 1,257,842 | 831,451 | 464,987 |
| Capital Expenditure | -42,594 | -24,128 | -64,026 | -39,168 | -24,352 |
| Free Cash Flow | 205,195 | 62,195 | 1,193,816 | 792,283 | 440,635 |